Reductionism and complexity in nanoparticle-vectored drug targeting

Journal of Controlled Release

Volumn 161, Issue 2, 2012, Pages 399-402

  Florence, Alexander T ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Complexity; Drug targeting; Nanoparticles; Reductionism

Indexed keywords

COMPLEX BIOLOGICAL SYSTEMS; COMPLEXITY; DRUG-TARGETING; NANO PARTICULATES; REDUCTIONISM; THEORETICAL INVESTIGATIONS;

DISSECTION; DRUG DELIVERY; PHYSICAL CHEMISTRY;

NANOPARTICLES;

DOXORUBICIN; NANOPARTICLE;

DRUG DELIVERY SYSTEM; DRUG TARGETING; EMPIRICISM; EXPERIMENTAL STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REDUCTIONISM; REVIEW; STOCHASTIC MODEL; THEORETICAL STUDY;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84862638401     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.11.005     Document Type: Review

References (26)

1. Wikipedia at http://en.wikipedia.org/wiki/Reductionism.
2. R.E. Ulanowicz, A third window: natural life beyond Newton and Darwin, Templeton Foundation Press, West Conshohocken, PA, 2009.
3. M.H.V. Van Regensmortel, Reductionism and complexity in molecular biology, EMBO Rep. 5 (2004) 1016-1020.
4. U. Alon, Simplicity in biology, Nature 444 (2007) 497.
5. P. Ruenraroengsak, J.M. Cook, A.T. Florence, Nanosystem drug targeting: facing up to complex realities, J. Control. Release 141 (2010) 265-276.
6. T. Laitala-Leinonen, Unsatsfactory gene transfer into bone-resorbing osteoclasts with liposomal transfection systems, J. Negat. Results Biomed. 4 (2005) 1-8.
7. Y.H. Bae, K. Park, Targeted drug delivery to tumours: myths, reality and possibility, J. Control. Release 153 (2011) 198-205.
8. P. Couvreur, Les nanotechnologies peuvent-elles contribuer à traiter des maladies sévères? Collège de France: Fayard, Paris, 2010.
9. M. Welter, H. Rieger, Physical determinants of vascular network remodeling during tumor growth, Eur. Phys. J. E Soft Matter 33 (2010) 149-163.
10. D.W. Bartlett, H. Su, I.J. Hildebrandt, W.A. Weber, M.E. Davis, Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 15549.
11. V. Torchilin, How do polymers prolong circulation time of liposomes? J. Liposome Res. 6 (1996) 99-116.
12. S.M. Moghimi, A.C. Hunter, C.M. Dadswell, S. Savay, C.R. Alving, J. Szebeni, Causative factors behind poloxamer 188 (Pluronic F68, Flocor™)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels, Biochim. Biophys. Acta 1689 (2011) 103-113.
13. E.C. Cho, Q. Zhang, Y. Xia, The effect of sedimentation and diffusion on cellular uptake of gold nanoparticles, Nat. Nanotechnol. 6 (2011) 385-391.
14. N. Hussain, B. Singh, T. Sakthivel, A.T. Florence, Formulation and stability of surface tethered DNA-gold-dendron nanoparticles, Int. J. Pharm. 25 (2003) 27-31.
15. E. Guazzelli, Sedimentation of particles: how can such a simple problem be so difficult? American Physics Society 58th Annual Meeting Division of Fluid Dynamics, Chicago, 2005.
16. B. Singh, A.T. Florence, Hydrophobic dendrimer-derived nanoparticles, Int. J. Pharm. 298 (2005) 348-353.
17. P. Sommerfeld, U. Schroeder, B.A. Sabel, Long term stability of PBCA nanoparticle suspensions suggest clinical usefulness, Int. J. Pharm. 155 (1997) 201-207.
18. I.F. Uchegbu, J.A. Double, J.A. Turton, A.T. Florence, Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse, Pharm. Res. 12 (1995) 1019-1024.
19. S. Fredenberg, M. Wahlgren, M. Reslow, A. Axelsson, The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems - a review, Int. J. Pharm. 415 (2011) 34-52.
20. A. Saleem, P.M. Price, Early tumor drug pharmacokinetics is influenced by tumor perfusion but not plasma drug exposure, Clin. Cancer Res. 14 (2008) 8184-8190.
21. M.J. Williamson, M.D. Silva, J. Terkelsen, et al., The relationship among tumor architecture, pharmacokinetics, pharmacodynamics and efficacy of bortezomib in mouse xenograft models, Mol. Cancer Ther. 8 (2009) 3234.
22. H.D. Summers, P. Ress, M.D. Holton, M.R. Brown, et al., Statistical analysis of nanoparticle dosing in a dynamic cellular system, Nat. Nanotechnol. 6 (2011) 170-174.
23. R. Erban, S.J. Chapman, Realistic boundary conditions for stochastic simulations of reaction-diffusion processes, Phys. Biol. 4 (2006) 16-28.
24. S.A. Isaacson, C.S. Peskin, Incorporating diffusion in complex geometries into stochastic chemical kinetics simulations, SIAM J. Sci. Comput. 28 (2006) 47-74.
25. P. Decuzzi, M. Ferrari, Design maps for nanoparticles targeting the diseased microvasculature, Biomaterials 29 (2008) 377-384.
26. T. Hara, S. Iriyama, K. Makino, H. Terada, M. Oha, Mathematical description of drug movement into tumor with EPR effect and estimation of its configuration for DDS, Colloids Surf. B Biointerfaces 75 (2010) 42-46.